Our Take
The achievement is real but narrow: a proof of concept in rodents that solves a hard targeting problem, not yet a clinical candidate or a path around delivery, the actual bottleneck in CRISPR oncology.
Why it matters
p53 mutations drive 50% of all cancers and up to 90% of pancreatic, ovarian, and lung tumors, yet no approved drugs exist because the protein lacks a binding pocket for conventional therapies. A CRISPR approach that can distinguish disease from healthy cells by a single nucleotide difference opens a new attack surface on tumors once considered untargetable.
Do this week
Cancer drug developers: audit your pipeline for p53-driven programs currently shelved due to undruggability; contact IGI or UC Berkeley for licensing discussions before competing CRISPR oncology programs announce similar results.
RNA-guided precision targets cancer's most mutated gene
Jingkun Zeng and colleagues at Jennifer Doudna's lab at UC Berkeley, working with UCSF, Gladstone Institutes, and the Innovative Genomics Institute, published a study in Nature showing a CRISPR-Cas12a2 system that selectively destroys cancer cells by recognizing mutant p53 mRNA transcripts. The system works by chromatin shredding: once it identifies a cancer-specific mutation in p53, it triggers cell death.
The approach demonstrates single-nucleotide discrimination. Zeng told GEN: "It's the first time we managed to target p53 with such precision," meaning the guide RNA can distinguish healthy cells from diseased ones where DNA differs by just one base pair. In mouse models of lung and liver tumors, the strategy proved effective.
The choice of p53 is not arbitrary. Mutations in this tumor suppressor occur in nearly half of all cancers and account for 70–90% of cases in the deadliest forms: ovarian, pancreatic, and non-small cell lung cancer. Despite decades of drug discovery effort, no approved p53 therapy exists on the market.
p53 has been untargetable because it lacks a binding pocket
Traditional cancer drugs work by inhibiting disease-driving proteins. p53 is the inverse problem: you must activate a tumor suppressor, and do so without restoring function in healthy cells. Small molecules and antibodies require a well-defined binding pocket; p53 does not have one, which is why it stayed undruggable despite its obvious therapeutic value.
CRISPR bypasses the binding-pocket constraint entirely. Instead of binding a protein surface, the system uses RNA guidance to recognize mRNA transcripts unique to cancer cells, then cuts the chromatin of those cells. The method is programmable for multiple mutations simultaneously and could extend beyond p53 to viral-infected cells or age-driven abnormalities, according to the authors.
The work sits within a broader industry push to move CRISPR beyond single-point-mutation correction (where it has shown clinical success, such as in the case of Baby KJ's metabolic disorder) into the messier biology of cancer, where hundreds of thousands of mutations can drive disease.
Delivery remains the real hurdle
The authors acknowledge that improving delivery efficiency to cancer cells is a longstanding and unresolved challenge in CRISPR therapeutics. Mouse studies prove the concept works in vivo, but scaling from rodent tumors to human patients requires solving how to get CRISPR machinery into solid tumors at therapeutic concentration. This is the step that has slowed many CRISPR cancer programs.
The team is now collaborating to test the technology across additional cancer types, including brain, prostate, and ovarian cancers. Watch for early partnership announcements or IND applications as a signal that delivery work is advancing. Until then, this is a validated targeting mechanism, not yet a drug candidate.